$ARVN News

Stephens & Co. Reiterates Overweight on Arvinas, Maintains $18 Price Target

Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028

Full Transcript: Arvinas Q1 2026 Earnings Call

Arvinas Employees Give Back During Company-wide Impact Day

Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Barclays Maintains Overweight on Arvinas, Raises Price Target to $20

BTIG Maintains Buy on Arvinas, Raises Price Target to $18

Arvinas Inc (ARVN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Decline

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript

Arvinas Q1 Earnings Call Highlights

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas Q1 EPS $(0.90) Misses $(0.87) Estimate, Sales $15.600M Miss $18.097M Estimate

Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Citigroup Maintains Buy on Arvinas, Raises Price Target to $24

Citigroup Maintains Buy on Arvinas, Raises Price Target to $21

BTIG Maintains Buy on Arvinas, Raises Price Target to $16